Literature DB >> 33095415

EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.

Daichi Nishiyama1, Yoshiaki Chinen1,2, Reiko Isa1, Yuto Fujibayashi1, Saeko Kuwahara-Ota1, Junko Yamaguchi1, Tomoko Takimoto-Shimomura1, Yayoi Matsumura-Kimoto1, Taku Tsukamoto1, Yuji Shimura1, Tsutomu Kobayashi1, Shigeo Horiike1, Masafumi Taniwaki3, Hiroshi Handa4, Junya Kuroda5.   

Abstract

Multiple myeloma (MM) is cytogenetically, genetically and molecularly heterogenous even among subclones in one patient, therefore, it is essential to identify both frequent and patient-specific drivers of molecular abnormality. Following previous molecular investigations, we in this study investigated the expression patterns and function of the Ewing sarcoma breakpoint region 1 (EWSR1) gene in MM. The EWSR1 transcriptional level in CD138-positive myeloma cells was higher in 36.4% of monoclonal gammopathy of undetermined significance, in 67.4% of MM patients compared with normal plasma cells, and significantly higher in ten human myeloma-derived cell lines (HMCLs) examined. EWSR1 gene knockdown caused growth inhibition with an increase of apoptotic cells in NCI-H929 and KMS-12-BM cells. Gene expression profiling using microarray analysis suggested EWSR1 gene knockdown caused transcriptional modulation of several genes associated with processes such as cell proliferation, cell motility, cell metabolism, and gene expression. Of particular, EWSR1 gene knockdown caused upregulation of let-7c and downregulation of its known targets K-RAS and AKT. Finally, our analysis using community database suggested that high EWSR1 expression positively associates with poor prognosis and advanced disease stage in MM. These findings suggest that EWSR1 overexpression is a pro-oncogenic molecular abnormality that may participate in MM progression.

Entities:  

Keywords:  Cell motility; Cell proliferation; EWSR1; Multiple myeloma; microRNA

Mesh:

Substances:

Year:  2020        PMID: 33095415     DOI: 10.1007/s12185-020-03027-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  44 in total

Review 1.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

Review 2.  Immunopathogenesis and immunotherapy of multiple myeloma.

Authors:  Hideto Tamura
Journal:  Int J Hematol       Date:  2018-01-24       Impact factor: 2.490

3.  Improved survival of older patients with multiple myeloma in the era of novel agents.

Authors:  Ulrich J M Mey; Christoph Leitner; Christoph Driessen; Richard Cathomas; Dirk Klingbiel; Felicitas Hitz
Journal:  Hematol Oncol       Date:  2015-04-21       Impact factor: 5.271

4.  Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.

Authors:  Gang An; Yuting Yan; Yan Xu; Xuehan Mao; Jiahui Liu; Huishou Fan; Qi Wang; Chenxing Du; Zengjun Li; Shuhua Yi; Rui Lv; Shuhui Deng; Weiwei Sui; Mingwei Fu; Mu Hao; Wenyang Huang; Dehui Zou; Yaozhong Zhao; Chenglu Yuan; Xin Du; Jianxiang Wang; Tao Cheng; Yu-Tzu Tai; Nikhil C Munshi; Lugui Qiu
Journal:  Leukemia       Date:  2019-10-07       Impact factor: 11.528

5.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

Review 6.  Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.

Authors:  Luca Agnelli; Pierfrancesco Tassone; Antonino Neri
Journal:  Expert Opin Biol Ther       Date:  2013-04-24       Impact factor: 4.388

Review 7.  A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.

Authors:  Christian M Schürch; Leo Rasche; Leonie Frauenfeld; Niels Weinhold; Falko Fend
Journal:  Virchows Arch       Date:  2019-12-17       Impact factor: 4.064

8.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Authors:  S K Kumar; A Dispenzieri; M Q Lacy; M A Gertz; F K Buadi; S Pandey; P Kapoor; D Dingli; S R Hayman; N Leung; J Lust; A McCurdy; S J Russell; S R Zeldenrust; R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

Review 9.  Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Authors:  C S Chim; S K Kumar; R Z Orlowski; G Cook; P G Richardson; M A Gertz; S Giralt; M V Mateos; X Leleu; K C Anderson
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528

10.  Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.

Authors:  S Ozaki; H Handa; T Saitoh; H Murakami; M Itagaki; H Asaoku; K Suzuki; A Isoda; M Matsumoto; M Sawamura; J Konishi; K Sunami; N Takezako; S Hagiwara; Y Kuroda; T Chou; E Nagura; K Shimizu
Journal:  Blood Cancer J       Date:  2015-09-18       Impact factor: 11.037

View more
  2 in total

1.  Identification of Hub Genes Associated With the Development of Stomach Adenocarcinoma by Integrated Bioinformatics Analysis.

Authors:  Kehui Zhang; Jian Wang; YingYing Zhu; Xiaolin Liu; Jiacheng Li; Zhe Shi; Mengxing Cao; Yong Li
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

2.  Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.

Authors:  Weijie Jiang; Tao Wu; Xuan Shi; Jiawen Xu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.